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Abstract: Alzheimer’s disease (AD) is characterized by extracellular plaques in the brain, mainly
consisting of amyloid-β (Aβ), as derived from sequential cleavage of the amyloid precursor protein.
Epidemiological studies suggest a tight link between hypovitaminosis of the secosteroid vitamin D
and AD. Besides decreased vitamin D level in AD patients, an effect of vitamin D on Aβ-homeostasis
is discussed. However, the exact underlying mechanisms remain to be elucidated and nothing is
known about the potential effect of vitamin D analogues. Here we systematically investigate the effect
of vitamin D and therapeutically used analogues (maxacalcitol, calcipotriol, alfacalcidol, paricalcitol,
doxercalciferol) on AD-relevant mechanisms. D2 and D3 analogues decreased Aβ-production and
increased Aβ-degradation in neuroblastoma cells or vitamin D deficient mouse brains. Effects were
mediated by affecting the Aβ-producing enzymes BACE1 and γ-secretase. A reduced secretase
activity was accompanied by a decreased BACE1 protein level and nicastrin expression, an essential
component of the γ-secretase. Vitamin D and analogues decreased β-secretase activity, not only
in mouse brains with mild vitamin D hypovitaminosis, but also in non-deficient mouse brains.
Our results further strengthen the link between AD and vitamin D, suggesting that supplementation
of vitamin D or vitamin D analogues might have beneficial effects in AD prevention.
Keywords: vitamin D; vitamin D analogues; amyloid precursor protein; amyloid-β; secretases;
Aβ-degradation
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1. Introduction
The most important pathological hallmarks of Alzheimer’s disease (AD), which is a progressive
neurodegenerative disorder, are extracellular plaques that are composed of aggregated Aβ peptides
and intracellular neurofibrillary tangles, consisting of hyperphosphorylated Tau proteins [1–4].
Aβ-generation depends on initial cleavage of the amyloid precursor protein (APP) by β-secretase
1 (BACE1), followed by intramembrane cleavage of APP by γ-secretase, a heterotetrameric protein
complex consisting of presenilin 1 or 2 (PS1, PS2), nicastrin, anterior-pharynx-defective 1a or 1b (Aph1a,
Aph1b), and presenilin-enhancer 2 (PEN2) [5–8]. Besides amyloidogenic, Aβ-releasing processing
of APP, APP can be shed by α-secretases in a non-amyloidogenic pathway [9–12]. The α-secretases
cleave APP within the Aβ domain and preclude the formation of Aβ peptides. Total Aβ level
is not only dependent on the proteolytic activities of the APP cleaving secretases, but also on
Aβ-degradation, involving e.g., the Aβ degrading enzymes neprilysin (NEP) and insulin-degrading
enzyme (IDE) [13,14]. In addition to several lipids that influence the generation, degradation, and
aggregation of Aβ peptides [15–25], it has recently been shown that fat soluble vitamins affect
molecular mechanisms that are involved in AD pathogenesis, e.g., Aβ-induced neurotoxicity, oxidative
stress, inflammatory processes, as well as Aβ-generation, Aβ-degradation, and Aβ-clearance [26–31].
Several vitamins, including vitamin A, provitamin Aβ-carotene, vitamin D3, vitamin K, and vitamin
E, have also been reported to be reduced in plasma/serum of AD patients [30,32–36] and vitamin D
hypovitaminosis affects up to 90% of the elderly population [37]. The biological activity of vitamin
D can be attributed to binding interactions with the vitamin D receptor (VDR), which undergoes a
conformational change, allowing for an interaction with the retinoid X receptor (RXR). The VDR-RXR
heterodimer is considered to be the active complex that binds to vitamin D response elements in the
DNA of target genes [38,39]. The VDR as well as the 1α-hydroxylase (CYP27B1), which converts 25(OH)
vitamin D3 (calcifediol) into its active form 1,25(OH)2 vitamin D3 (calcitriol), have been shown to be
expressed in human brain [40], and vitamin D and vitamin D metabolites have been reported to cross
the blood-brain-barrier [41]. Recently, we and others could show that vitamin D deficiency causes an
increase in amyloidogenic β-secretase cleavage of APP and a decrease in Aβ-degradation, resulting in
elevated Aβ level [29,42]. In line, 25(OH) vitamin D supplementation elevated Aβ-degradation due to
increased NEP expression and activity [29], supporting vitamin D supplementation as a novel approach
to treat AD. In the present study, we compare these effects as mediated by vitamin D with vitamin D
analogues on their amyloidogenic potential by investigating the APP processing pathways, as well as
Aβ-degradation. Experiments were performed in neuroblastoma cells, revealing a concentration of
approximately 2.5 ng/mL 25(OH) vitamin D3 [29]. However, it has to be pointed out that, although
neuroblastoma cell lines have some neuronal properties, substantial differences when compared to
neurons exist, which is a caveat of the study. Therefore, the main results were also validated ex vivo in
homogenates of wildtype (wt) and hypovitaminosis D mouse brains. Further studies are needed to
verify the potential positive effects of vitamin D and its analogues in vivo.
We selected 25(OH) vitamin D3 (calcifediol), which is converted by CYP27B1 to
1,25-dihydroxyvitamin D3, the natural vitamin D hormone, and therapeutically used analogues
of vitamin D3 and D2 (Figure 1). Vitamin D analogues are modified in the side-chain portion
of the molecule and exert a lower calcemic activity than natural vitamin D3, but retain many
therapeutic properties of 1,25-dihydroxyvitamin D3. The 1,25-hydroxylated vitamin D3 analogue,
maxacalcitol, is used to treat renal patients that are affected by secondary hyperparathyroidism, while
the 1,24-hydroxylated vitamin D3 analogue calcipotriol for treatment of psoriasis and 1-hydroxylated
alfacalcidol is administered to treat osteoporosis and secondary hyperparathyroidism. Paricalcitol
and doxercalciferol were selected as vitamin D2 analogues. Identical to the vitamin D3 analogue
maxacalcitol, paricalcitol contains a hydroxyl group at C1 and C25, but a vitamin D2 instead of a vitamin
D3 side chain. 1-hydroxylated doxercalciferol is the vitamin D2 analogue that is comparable to the
vitamin D3 analogue alfacalcidol in regard of the hydroxylation status. Both vitamin D2 analogues
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are used to treat elevated serum parathyroid hormone levels that are associated with secondary
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also showed significantly reduced Aβ level to 78.2% and 68.2%, respectively (maxacalcitol: 78.2 ± 
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analogues also significantly reduced the Aβ level. The determination of total Aβ level of paricalcitol 
treated cells, a 1,25-hydroxylated vitamin D2 analogue, revealed a significant reduction to 56.3% 
(paricalcitol: 56.3 ± 8.2%, p = 0.005). The 1-hydroxylated vitamin D2 analogue doxercalciferol 
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analogues of vitamin D3 and D2 significantly reduced total Aβ level to 66.8% (mean analogues: 66.8 ± 
Figure 1. Chemical structure of 25(OH) vitamin D3 and different vitamin D analogues. Structural
changes between the analogues are highlighted in red or with red cycles.
2. Results
2.1. Vitamin D Analogues Decrease Total Aβ Level
In order to analyze whether analogues of vitamin D3 and vitamin D2 have similar
anti-amyloidogenic properties when compared to 25(OH) vitamin D3 [29], we examined total secreted
Aβ level in the human neuroblastoma cell line SH-SY5Y stably transfected with human APP695,
the major isoform that is found in neurons [45], in the presence of calcifediol (25(OH) vitamin D3),
maxacalcitol, calcipotriol, and alfacalcidol (vitamin D3 analogues), as well as the vitamin D2 analogues
paricalcitol and doxercalciferol (Figure 1). We decided to use 25(OH) vitamin D3 instead of active
1,25(OH)2 vitamin D3 as calcifediol has a long serum half-life of approximately three weeks when
compared to the short serum half-life (4–6 h) of 1,25(OH)2 vitamin D3 [46]. Cells were treated for
24 h in presence of vitamin D or analogues and secreted Aβ level were examined by analyzing
the conditioned media of treated cells or control cells, incubated with the solvent EtOH. Vitamin
D and its analogues were incubated in a final concentration of 100 nM. The concentration that was
used corresponds to physiological serum concentrations of approximately 75 nmol/L [47,48], and
is frequently used for cell culture experiments [26,49,50]. Furthermore, no significant change in cell
viability was found using 100 nM vitamin D as compared to the solvent control (supplement Figure S1).
Moreover, it has to be mentioned that calcifediol is used as a therapeutical supplement to treat vitamin
D hypovitaminosis [51].
In presence of 25(OH) vitamin D3, calcifediol, which is converted by 1α-hydroxylase CYP27B1 to
1,25-dihydroxyvitamin D3, we found a significant reduction to 55.1% in total Aβ level when compared
to cells that are treated with the solvent control (calcifediol: 55.1 ± 4.2%, p ≤ 0.001) (Figure 2A).
The vitamin D3 analogues maxacalcitol (1,25-hydroxylated) and calcipotriol (1,24-hydroxylated) also
showed significantly reduced Aβ level to 78.2% and 68.2%, respectively (maxacalcitol: 78.2 ± 3.1%,
p = 0.031; calcipotriol: 68.2 ± 7.2%, p = 0.017). Alfacalcidol, a 1-hydroxylated vitamin D3 analogue,
decreased total Aβ level to 60.3% (alfacalcidol: 60.3 ± 4.3%, p = 0.002). Vitamin D2 analogues also
significantly reduced the Aβ level. The determination of total Aβ level of paricalcitol treated cells,
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a 1,25-hydroxylated vitamin D2 analogue, revealed a significant reduction to 56.3% (paricalcitol: 56.3
± 8.2%, p = 0.005). The 1-hydroxylated vitamin D2 analogue doxercalciferol revealed a significant
decrease to 70.9% (doxercalciferol: 70.9 ± 8.6%, p = 0.037). On average, mean analogues of vitamin
D3 and D2 significantly reduced total Aβ level to 66.8% (mean analogues: 66.8 ± 3.9%, p ≤ 0.001)
(Figure 2A). However, no significant differences in the Aβ level were obtained between single vitamin
analogues as determined by ANOVA analysis.
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Figure 2. Effect of vitamin D and analogues on Aβ generation. Cells were treated with 25(OH) 
vitamin D3 (calcifediol), the vitamin D3 analogues maxacalcitol, calcipotriol, alfacalcidol, the vitamin 
D2 analogues paricalcitol, doxercalciferol in a final concentration of 100 nM or solvent control 
(EtOH). (A) Total secreted Aβ level in SH-SY5Y APP695 overexpressing cells (n = 3). Aβ of the 
conditioned media was analyzed by immunoprecipitation and Western Blot (WB) analysis. Using 
Post Hoc analysis, no significant differences between calcifediol and analogues were found in respect 
to their potential to reduce Aβ level. (B) Determination of α-secretase activity in living SH-SY5Y wt 
cells (n = 7). (C) Analysis of β-secretase activity in isolated membranes of SH-SY5Y wt cells (n = 7) and 
in living cells (n = 5). (D) β-secretase activity in three wt mouse brain and five vitamin D deficient 
mouse brain homogenates (n = 3). Vitamin D and analogues influence β-secretase activity in wt 
mouse brains and in vitamin D deficient mouse brains. (E) RT-PCR analysis of BACE1 in SH-SY5Y wt 
cells (n = 3). (F) Determination of BACE1 protein level in cell lysates of SH-SY5Y wt cells by WB 
analysis (n = 3). Control conditions were set to 100% and illustrated as a line in the graphic. Error bars 
represent the standard error of the mean. Asteriks show the statistical significance calculated by 
unpaired Student’s t test (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001).  
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Reduced total Aβ level can be caused by different mechanisms, including an increase in the 
non-amyloidogenic α-secretase dependent processing of APP. Therefore, we examined α-secretase 
activity in presence of 25(OH) vitamin D3 (calcifediol), vitamin D3 analogues, and vitamin D2 
analogues in living SH-SY5Y wt cells. The vitamin D3 analogues maxacalcitol, calcipotriol, and 
alfacalcidol and the vitamin D2 analogue doxercalciferol showed no significant effect on α-secretase 
activity (Figure 2B). In contrast, 25(OH) vitamin D3 calcifediol and the vitamin D2 analogue 
paricalcitol, being also hydroxylated at C25 like calcifediol, revealed a significant increase in 
α-secretase activity, to 114.5% and 113.9%, respectively (calcifediol: 114.5 ± 4.5%, p = 0.015; 
paricalcitol: 113.9 ± 4.7%, p = 0.023).  
2.3. Vitamin D Analogues Decrease Amyloidogenic β-Secretase Dependent APP Cleavage 
Cleavage of APP by BACE1 is the initial step in Aβ-production, generating the N-terminus of 
Aβ peptides. To evaluate whether vitamin D analogues have a direct effect on β-secretase activity, 
we prepared purified membranes of SH-SY5Y wt cells, incubated them with the vitamin D 
analogues, and measured β-secretase activity. 25(OH) vitamin D3, calcifediol, as well as all vitamin D 
analogues only slightly affected β-secretase activity directly, however, except for calcifediol, the 
observed reduction in β-secretase activity was statistically significant (maxacalcitol: 91.7 ± 2.3%, p = 
0.016; calcipotriol: 94.7 ± 1.0%, p = 0.023; alfacalcidol: 94.1 ± 1.3%, p = 0.018; paricalcitol: 93.2 ± 1.6%, p 
= 0.013; and doxercalciferol: 90.7 ± 1.0%, p ≤ 0.001) (Figure 2C). To validate these results, we analyzed 
β-secretase activity in living SH-SY5Y wt cells. Vitamin D or vitamin D analogue supplemented cells 
revealed a more pronounced effect on β-secretase activity. Calcifediol significantly reduced 
β-secretase activity to 74.4%, the vitamin D3 analogues maxacalcitol and alfacalcidol showed a 
reduction to 69.2% and 67.5%, respectively (calcifediol: 74.4 ± 6.3%, p = 0.009; maxacalcitol: 69.2 ± 
5.0%, p = 0.0014; alfacalcidol: 67.5 ± 7.1%, p = 0.004) (Figure 2C). Calcipotriol showed a 
Figure 2. Effect of vitamin D and analogues on Aβ generation. Cells were treated with 25(OH)
vitamin D3 (calcifediol), the vitamin D3 analogues maxacalcitol, calcipotriol, alfacalcidol, the vitamin
D2 analogues paricalcitol, doxercalciferol in a final concentration of 100 nM or solvent control (EtOH).
(A) Total secreted Aβ level in SH-SY5Y APP695 overexpressing cells (n = 3). Aβ of the conditioned
media was analyzed by immunoprecipitation and Western Blot (WB) analysis. Using Post Hoc analysis,
no significant differences between ca cifediol and nalogues were found in respect to their potential
to reduce Aβ level. (B) Determination of α-secretas activity in living SH-SY5Y wt cells (n = 7).
(C) Analysis of β-secretase activity in isolated membranes of SH-SY5Y wt cells (n = 7) and in living
cells (n = 5). (D) β-secretase activity in three wt mouse brain and five vitamin D deficient mouse
brain homogenates (n = 3). Vitamin D and analogues influence β-secretase activity in wt mouse brains
and in vitamin D deficient mouse brains. (E) RT-PCR analysis of BACE1 in SH-SY5Y wt cells (n = 3).
(F) Determination of BACE1 protein level in cell lysates of SH-SY5Y wt cells by WB analysis (n = 3).
Control conditions were set to 100% and illustrated as a line in the graphic. Error bars represent the
standard error of the mean. Asteriks show the statistical significance calculated by unpaired Student’s
t test (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001).
2.2. Analysis of Non-Amyloidogenic APP Shedding in Presence of Vitamin D Analogues
Reduced total Aβ level can be caused by different mechanisms, including an increase in the
non-amyloidogenic α-secretase dependent processing of APP. Therefore, we examined α-secretase
activity in presence of 25(OH) vitamin D3 (calcifediol), vitamin D3 analogues, and vitamin D2 analogues
in living SH-SY5Y wt cells. The vitamin D3 analogues maxacalcitol, calcipotriol, and alfacalcidol
and the vitamin D2 analogue doxercalciferol showed no significant effect on α-secretase activity
(Figure 2B). In contrast, 25(OH) vitamin D3 calcifediol and the vitamin D2 analogue paricalcitol, being
also hydroxylated at C25 like calcifediol, revealed a significant increase in α-secretase activity, to 114.5%
and 113.9%, respectively (calcifediol: 114.5 ± 4.5%, p = 0.015; paricalcitol: 113.9 ± 4.7%, p = 0.023).
2.3. Vitamin D Analogues Decrease Amyloidogenic β-Secretase Dependent APP Cleavage
Cleavage of APP by BACE1 is the initial step in Aβ-production, generating the N-terminus
of Aβ peptides. To evaluate whether vitamin D analogues have a direct effect on β-secretase
activity, we prepared purified membranes of SH-SY5Y wt cells, incubated them with the vitamin D
analogues, and measured β-secretase activity. 25(OH) vitamin D3, calcifediol, as well as all vitamin
D analogues only slightly affected β-secretase activity directly, however, except for calcifediol, the
observed reduction in β-secretase activity was statistically significant (maxacalcitol: 91.7 ± 2.3%,
p = 0.016; calcipotri l: 94.7± 1.0%, p = 0.023; alfacalcidol: 94.1± 1.3%, p = 0.018; pari lcitol: 93.2± 1.6%,
p = 0.013; and doxercalciferol: 90.7± 1.0%, p≤ 0.001) (Figure 2C). To va idate these resu t , we analyzed
β-secretase activity in living SH-SY5Y wt cells. Vitamin D or vitamin D analogue supplemented cells
revealed a more pronounced effect on β-secretase activity. Calcifediol significantly reduced β-secretase
activity to 74.4%, the vitamin D3 analogues maxacalcitol and alfacalcidol showed a reduction to 69.2%
and 67.5%, respectively (calcifediol: 74.4 ± 6.3%, p = 0.009; maxacalcitol: 69.2 ± 5.0%, p = 0.0014;
alfacalcidol: 67.5 ± 7.1%, p = 0.004) (Figure 2C). Calcipotriol showed a non-significant decrease
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in β-secretase activity to 88.8% (calcipotriol: 88.8 ± 3.1%, p = 0.06). Additionally, the vitamin D2
analogues, paricalcitol and doxercalciferol, provided with a markedly reduction to 61.9% and 77.3%,
a more pronounced effect in metabolically active cells when compared to β-secretase measurement of
supplemented isolated membranes (Figure 2C). This indicates that beside the direct effect, indirect
mechanisms, like gene expression or protein stability, contribute to the observed decrease in β-secretase
activity. This observation is substantiated by the finding that all of the analogues averaged significantly
reduced β-secretase activity in living cells to 72.9% (mean analogues, living cells: 72.9 ± 4.7%,
p ≤ 0.001), whereas this effect was alleviated in direct β-secretase activity measurements (mean
analogues, cellular membranes: 92.5 ± 0.8%, p = 0.004) (Figure 2C). Notably, calcifediol treated
cells, which showed a reduction in β-secretase activity to 74.4% in living cells, reveal a nearly
identical decrease in soluble β-secreted APP (sAPPβ) level to 76.9% (sAPPβ: 76.9 ± 1.8%, p = 0.0018)
(supplement Figure S2), further underlining the data observed by the fluorescence resonance energy
transfer (FRET)-based β-secretase assay.
To further examine the potential of vitamin D analogues to decrease Aβ level by reducing
β-secretase activity in an ex vivo situation, we analyzed vitamin D deficient mouse brains showing
a 23% reduction in the 25(OH) vitamin D level as compared to wt mouse brains [29], either
supplemented with vitamin D or unsupplemented. Therefore, we used homogenates of vitamin
D deficient and wt mouse brains, and measured β-secretase activity in the presence or absence of
vitamin D analogues. As already shown in our previous study [29] we found a significant increase
in β-secretase activity in vitamin D deficient mouse brains when compared to wt mouse brains
(Figure 2D). Supplementing of vitamin D deficient mouse brains with vitamin D3 or vitamin D3 and
D2 analogues revealed the following results: five out of six analyzed vitamins showed a decrease in
β-secretase activity, resulting in a partial rescue of β-secretase activity obtained for unsupplemented wt
mouse brains. However, only calcifediol and doxercalciferol reached a level of significance (calcifediol,
p = 0.026; doxercalciferol: p = 0.040; Table 1). Four out of six vitamins/analogues tended to decrease
β-secretase activity when supplemented on wt mouse brains; three vitamin D species, calcifediol,
alfacalcidol and maxacalcitol, revealed a significant reduction in β-secretase activity (calcifediol,
p = 0.028; alfacalcidol, p = 0.050; maxacalcitol, p = 0.015). Analyzing the effect of all of the analogues
averaged on either wt mouse brains or vitamin D deficient mouse brains, we found a similar decrease in
β-secretase activity (Figure 2D), suggesting that both individuals with hypovitaminosis and individuals
with normal vitamin D status, might profit from vitamin D supplementation in a similar range, which
should be evaluated in further studies. A more detailed statistical analysis is given in Tables 1 and 2.
Table 1. Comparison between β-secretase activity in supplemented (WT+; 100 nM calcifediol or
its analogues) and unsupplemented (WT-) wildtype mouse brains and in supplemented (deficient+;
100 nM calcifediol or its analogues) and unsupplemented (deficient-) vitamin D deficient mouse brains.
Analogues Statistical Test
WT+ WT+ WT+ WT- WT- Deficient+
WT− Deficient+ Deficient− Deficient+ Deficient− Deficient−
calcifediol
t test 1 0.028 0.000 0.000 0.005 0.000 0.026
Bonferroni 2 0.039 0.000 0.000 0.099 0.001 0.450
alfacalcidol
t test 0.050 0.000 0.000 0.003 0.000 0.144
Bonferroni 0.239 0.000 0.000 0.010 0.000 0.878
calcipotriol t test 0.858 0.002 0.002 0.000 0.000 0.964
Bonferroni 1.000 0.001 0.001 0.002 0.002 1.000
doxercalciferol
t test 0.573 0.499 0.014 0.145 0.000 0.040
Bonferroni 1.000 1.000 0.038 0.873 0.005 0.226
maxacalcitol
t test 0.015 0.000 0.000 0.001 0.000 0.606
Bonferroni 0.167 0.000 0.000 0.001 0.000 1.000
paricalcitol t test 0.179 0.000 0.000 0.000 0.000 0.223
Bonferroni 0.945 0.000 0.000 0.000 0.000 1.000
1 Student’s t test was used to compare two groups. 2 Bonferroni was used to compare more than two groups.
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Table 2. Comparison of the effects of calcifediol and its analogues on β-secretase activity in either WT
or vitamin D deficient mouse brains. No significant differences between calcifediol and the analogues




















maxacalcitol paricalcitol 1.000 1.000
As described above, we observed a more pronounced reduction in β-secretase activity in living
cells in presence of vitamin D analogues when compared to the direct effect of these substances on
β-secretase activity. To examine whether vitamin D analogues decrease β-secretase activity by affecting
the gene expression of BACE1, we performed qPCR analysis of BACE1 and determined BACE1 protein
level by WB analysis in SH-SY5Y wt cells. Except for paricalcitol, all vitamin D3 and vitamin D2
analogues, as well as calcifediol, tended to decrease BACE1 gene expression (Figure 2E).
Significant results were only obtained for calcifediol, calcipotriol, and alfacalcidol (calcifediol:
80.8 ± 2.9%, p = 0.003; calcipotriol: 75.4 ± 8.1%, p = 0.040; alfacalcidol: 70.3 ± 5.4%, p = 0.006).
The reason why paricalcitol showed no effect on BACE1 gene expression remains speculative.
Paricalcitol, a third generation analogue of vitamin D2, is an activator of VDR and is used for secondary
hyperparathyroidism. When compared to calcitriol, different effects were observed e.g., a reduced
stimulation of the intestinal calcium transport proteins or a reduced effect on calbindin expression [52].
Similar mechanisms might be responsible for an absent effect on BACE1 expression in the presence of
paricalcitol. However, the underlying mechanisms remain to be elucidated.
On average, all of the analogues revealed a significant reduction in BACE1 gene expression
to 82.1% (mean analogues: 82.1 ± 4.6%, p = 0.005) (Figure 2E). In accordance with these results,
analyzing BACE1 protein level by WB analysis, all vitamin D analogues revealed significant results.
In the presence of calcifediol or the vitamin D3 and vitamin D2 analogues, BACE1 protein level was
significantly reduced (Figure 2F and supplement Figure S3). 25(OH) vitamin D3, calcifediol, showed
the most pronounced reduction in BACE1 protein level to 54.1% (calcifediol: 54.1 ± 5.7%, p = 0.004)
(Figure 2F). The vitamin D3 analogues maxacalcitol, calcipotriol, and alfacalcidol revealed a 20 to
30% reduction in BACE1 protein level. For alfacalcidol, the decrease did not reach a significant level
(maxacalcitol: 71.4 ± 5.8%, p = 0.020; calcipotriol: 68.9 ± 2.8%, p = 0.009; alfacalcidol: 77.6 ± 8.4%,
p = 0.099). A significant reduction in BACE1 protein level to 63.2% and 74.3%, respectively, was
also obtained for the vitamin D2 analogues paricalcitol and doxercalciferol (paricalcitol: 63.2 ± 4.2%,
p = 0.005; doxercalciferol: 74.3 ± 5.4%, p = 0.025). All of the analogues averaged showed a significant
decrease in BACE1 protein level to 71.1% (mean analogues: 71.1 ± 2.5%, p = 0.011) (Figure 2F), which
is in line with the decreased BACE1 expression to 82.1%.
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2.4. Vitamin D Analogues Decrease γ-Secretase Processing of APP
Beside the observed potency of vitamin D3 and vitamin D2 analogues to reduce amyloidogenic
β-secretase dependent APP processing we analyzed whether γ-secretase activity, releasing Aβ peptides,
is also affected in presence of these substances. As the effect for the vitamin D analogues was
more prominent in cultured cells when compared to isolated membranes, and as effects on gene
expression and protein level were found in case of β-secretase cleavage, we analyzed γ-secretase
activity in metabolically active cells. When compared to cells treated with the solvent control calcifediol,
maxacalcitol, alfacalcidol, paricalcitol, and doxercalciferol showed a significant reduction in γ-secretase
activity, whereas calcipotriol did not affect γ-secretase activity (calcifediol: 85.3 ± 2.5%, p ≤ 0.001;
maxacalcitol: 91.3 ± 3.0%, p = 0.039; alfacalcidol: 74.7 ± 3.3%, p ≤ 0.001; paricalcitol: 80.6 ± 4.0%,
p = 0.0014; doxercalciferol: 80.2 ± 4.3%, p = 0.0017) (Figure 3A). All of the vitamin D analogues
averaged significantly reduced γ-secretase activity to 86.1% (mean analogues: 86.1 ± 3.4%, p = 0.003).
A significant reduction in gene expression of the γ-secretase component nicastrin was found for
calcifediol, calcipotriol, alfacalcidol, paricalcitol, and doxercalciferol (calcifediol: 83.3 ± 4.1%, p = 0.015;
calcipotriol: 83.9 ± 2.8%, p = 0.005; alfacalcidol: 83.1 ± 3.6%, p = 0.009; paricalcitol: 88.5 ± 3.2%,
p = 0.023; doxercalciferol: 82.8 ± 2.7%, p = 0.003) (Figure 3B). Maxacalcitol showed a non-significant
reduction in nicastrin mRNA levels to 91.3%. The average of all the analogues also revealed a significant
reduction to 85.9% (mean analogues: 85.9 ± 1.7%, p ≤ 0.001), which is comparable to the observed
reduction in secretase activity to 86.1%.
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2.5. Vitamin D3 and Vitamin D2 Analogues Increase Aβ-Degradation
In order to investigate whether vitamin D3 and vitamin D2 analogues affect Aβ-degradation,
we used mouse neuroblastoma N2a cells and treated these cells with vitamin analogues in presence of
human synthetic Aβ peptides. Remaining synthetic Aβ peptides were detected by WB analysis, using
an antibody recognizing human but not endogenous mouse Aβ. In the presence of 25(OH) vitamin D3,
calcifediol, Aβ-degradation was significantly increased to 119.6% (calcifediol: 119.6 ± 4.5%, p = 0.034)
(Figure 4A). The 1,25-hydroxylated and 1,24-hydroxylated vitamin D3 analogues maxacalcitol and
calcipotriol increased Aβ-degradation to 164.5% and 202.1%, whereas the 1-hydroxylated vitamin D3
analogue alfacalcidol revealed an increase in Aβ-degradation that was similar to calcifediol (maxacalcitol:
164.5 ± 6.3%, p = 0.009; calcipotriol 202.1 ± 4.2%, p = 0.002; alfacalcidol: 123.5 ± 3.5%, p = 0.046)
(Figure 4A). An increased Aβ-degradation was also found for vitamin D2 analogues. 1,25-hydroxylated
paricalcitol elevated Aβ-degradation to 168.7%, 1-hydroxylated doxercalciferol to 158.2% (paricalcitol:
168.7± 2.6%, p = 0.002; doxercalciferol: 158.2± 2.8%, p = 0.003). The average of all vitamin D analogues
showed a significant increase in Aβ-degradation to 156.1% (mean analogues: 156.1 ± 3.2%, p ≤ 0.001)
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(Figure 4A). We analyzed whether vitamin D3 and vitamin D2 analogues also have the potential to
increase Aβ-degradation in vitamin D deficient mouse brains. Therefore, we incubated homogenates
of vitamin D deficient mouse brains with vitamin D analogues in an ex vivo experiment. Maxacalcitol,
calcipotriol, alfacalcidol and paricalcitol also significantly increased Aβ-degradation in case of vitamin
D deficiency (maxacalcitol: 128.3 ± 1.3%, p = 0.001; calcipotriol: 123.8 ± 6.2%, p = 0.041; alfacalcidol:
120.0 ± 4.5%, p = 0.027; paricalcitol: 112.2 ± 3.1%, p = 0.043), whereas calcifediol and doxercalciferol
did not affect Aβ-degradation in mouse brain homogenates of vitamin D deficient mice (Figure 4B).
Again, on average, all of the analogues revealed a significant increase in Aβ-degradation in vitamin D
deficient mouse brains to 119.2% (mean analogues: 119.2 ± 3.2%, p ≤ 0.001).
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Figure 4. Effect of vitamin D and analogues on Aβ catabolism. Vitamin D and its analogues influence
Aβ-degradation. T t l ti in (A) mouse neuroblastoma N2a wt cells (n = 3) and (B) vitamin
D deficient mouse brain (n = 5). Calcifediol and its analogues increased the Aβ-degradation compared
to solv nt control. (C) RT-PCR analysis of NEP expression in SH-SY5Y wt cells (n = 3). (D) NEP activity
in N2a cells ( = 8). Error bars represent the standard error of the mean. Asteriks show the statistical
significance calculated by unpair Student’s t tes (* p ≤ 0.05; ** p ≤ 0.01; *** 0.001).
In line, RT-PCR analysis of treated human neuroblastoma cells SH-SY5Y revealed that vitamin
D and all of the analogues tended to increase NEP expression, one of the main enzymes known
to be involved in Aβ-degradation [13]. A significant increase in NEP gene expression was found
for alfacalcidol, maxacalcitol, and paricalcitol (alfacalcidol: 113.8 ± 5.0%, p = 0.021; maxacalcitol:
119.1± 7.3%, p = 0.026; paricalcitol 111.6± 3.0%, p = 0.003) (Figure 4C). The average of all the analogues
also showed a significant increase in NEP mRNA level to 110.7% (mean analogues: 110.7 ± 2.9%,
p = 0.007). Similarly, vitamin D and the analogues tended to increase NEP activity (Figure 4D), which is
again in line with elevated Aβ-degradation in presence of vitamin D or its analogues. Alfacalcidol and
paricalcitol, which already showed a significant increase in NEP gene expression, also revealed a significant
Int. J. Mol. Sci. 2017, 18, 2764 10 of 21
elevation in NEP activity (alfacalcidol: 165.2 ± 16.5%, p = 0.029; paricalcitol: 201.8 ± 35.3%, p = 0.029
(Figure 4D). All of the analogues averaged revealed a significant increase in NEP activity to 159.6% (mean
analogues: 159.6± 12.0%, p = 0.0011).
2.6. Influence of Vitamin D3 and Vitamin D2 Analogues on Inflammatory Processes
As inflammation plays a crucial role in AD, we also investigated whether vitamin D analogues
interfere with inflammatory processes. We selected cytokine Interleukin-1β (IL-1β), which is known
to initiate inflammatory responses [53] and reported to be elevated in brains of AD patients [54] to
analyze whether vitamin D3 and vitamin D2 analogues might reduce inflammatory responses and used
ELISA technique to determine IL-1β level. The vitamin D3 analogues maxacalcitol, calcipotriol, and
alfacalcidol significantly reduced IL-1β level to 71.4%, 84.4%, and 76.6%, respectively (maxacalcitol:
71.4± 9.3%, p = 0.044; calcipotriol: 84.4± 4.6%, p = 0.050; alfacalcidol: 76.6± 2.7%, p = 0.005) (Figure 5).
Calcifediol and doxercalciferol also showed the tendency to decrease IL-1β level, however, the observed
decrease did not reach statistical significance (calcifediol: 84.7 ± 8.4%, p = 0.167; doxercalciferol:
73.1 ± 9.4%, p = 0.054). Paricalcitol significantly increased IL-1β level (paricalcitol: 121.7 ± 6.8%,
p = 0.044) (Figure 5).
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determined by enzyme-linked immunosorbent assay (ELISA) technique (n 3). IL-1β was analyzed
in SH-SY5Y wt cells incubated with 100 nM calcifediol or analogues compared to cells treated with
the solvent control. Error bars represent the standard error of the mean. Asteriks show the statistical
significance calculated by unpaired Student’s t test (* p ≤ 0.05; ** p ≤ 0.01).
3. Discu sion
Besides the central role of vitamin D in calcium and phosphate homeo tasis, vitamin D
is di cussed to have neur protective and a ti-inflammato y p operties [55,56] and is important
for brain developme t influencing proliferation, differentiatio , neurite outgrowth, and neuronal
density [57,58]. Several studies also observed an a sociation betw en cognitive impairment and
vitamin D hypovitaminosis [59–64]. Moreover, Sutherland et al. reported a link betw en vitamin D
and AD, describing a reduction in VDR mRNA levels in hi pocampal CA1 and CA2 pyramidal cells
of AD patients when compared to patients that were su fering from Huntington disease [65]. Studies
during the past years su ges that lower vitamin D concentrations are a sociated with a substantially
increased risk of a l-cause dementia and AD [66–68]. Recently, okry et al. identified four single
nucleotide polymorphisms (SNPs) in the vitamin D pathway that are sign ficantly linked to AD [69].
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In our previous study, analyzing mild vitamin D deficiency, we found increased Aβ peptide level
caused by increased β-secretase cleavage of APP and decreased Aβ-degradation in vitamin D deficient
mouse brains [29]. The aim of the present study was to investigate whether therapeutically used
analogues of vitamin D3 and vitamin D2 also shows anti-amyloidogenic properties, and whether
differences exist between single vitamin D analogues. In agreement with increased Aβ peptide level
in the case of mild 25(OH) vitamin D3 deficiency, calcifediol, which is converted by 1α-hydroxylase
CYP27B1 to active 1,25(OH)2 vitamin D3, calcitriol, decreased total Aβ level to 55.1% in human
neuroblastoma cells. Also, the vitamin D3 analogues maxacalcitol, calcipotriol and alfacalcidol and the
vitamin D2 analogues paricalcitol and doxercalciferol significantly reduced Aβ level. No significant
differences were obtained between single vitamin D analogues. In line with our results, a similar
reduction of approximately 50% in Aβ40 and Aβ42 peptides and a decrease in the number of amyloid
plaques has also been shown in APP transgenic mice that were fed for five months with a vitamin D
enriched diet [70]. Beside the potential of vitamin D to reduce Aβ level it has been recently shown
that vitamin D3 protects against Aβ peptide cytotoxicity by reverting the Aβ1–42 induced reduction
in the sphingosine-1-phosphate/ceramide ratio [26]. We found that vitamin D3 and analogues of
vitamin D3 and D2 reduce secreted Aβ peptide level by decreasing amyloidogenic APP processing
and by an elevation of Aβ-degradation. Impaired amyloidogenic APP processing in presence of
vitamin D and vitamin D analogues is caused by a slight direct effect of these vitamins on β-secretase
activity, and by a decrease in BACE1 gene expression, accompanied by reduced BACE1 protein
level. Besides transcriptional effects, it cannot be excluded that altered BACE1 protein stability
in presence of vitamin D or vitamin D analogues might also contribute to the reduction in BACE1
protein level. BACE1 can be degraded by the lysosomal and ubiquitin-proteasome system (UPS) [71,72].
Interestingly, 1,25-dihydroxyvitamin D3 is involved in the regulation of numerous UPS genes, including
ubiquitinating and deubiquitinating enzymes [73]. In this respect, is has to be mentioned that BACE1
degradation is dependent on ubiquitin carboxyl-terminal hydrolase L1, a deubiquitinating enzyme
highly specific to neurons [74]. Furthermore, it could be recently shown that vitamin D deficiency
down-regulates genes that are involved in protein catabolism [75]. However, so far it is unclear
whether these mechanisms are also affected by vitamin D analogues, which has to be investigated in
further studies.
In analogy to our observed effect on BACE1 protein level, Briones et al. found a 24% reduction in
BACE1 protein level in old rats supplemented with vitamin D3 as compared to control animals [76].
In accordance to decreased BACE1 protein level in presence of vitamin D, silencing VDR in E16
primary rat cortical neurons increased mRNA and protein level of BACE1 [42], resulting in an increased
intracellular Aβ1–42 level. The vitamin D induced reduction in β-secretase APP cleavage could be
further substantiated ex vivo by supplementing vitamin D deficient and wt mouse brain homogenates
with vitamin D3 or analogues of vitamin D3 and vitamin D2, indicating that both, patients with
vitamin D hypovitaminosis and patients with a normal vitamin D status, might profit from vitamin
D supplementation. Beside the effect of vitamin D and its analogues on β-secretase, we found
significantly reduced γ-secretase activity in metabolically active cells in the presence of vitamin D or
vitamin D analogues. In accordance to reduced γ-secretase activity, we found significantly reduced
mRNA levels of nicastrin, indicating that altered gene expression of nicastrin, which is necessary for
the maturation of the γ-secretase complex [77,78], contributes to the observed reduction in γ-secretase
activity. Notably, the mRNA level of nicastrin have been shown to be increased in VDR silenced
primary rat cortical neurons [42], thus supporting our results. In addition to the important role of
β- and γ-secretase processing of APP in Aβ anabolism, Aβ level can be also decreased by elevated
non-amyloidogenic α-secretase processing of APP. However, the effect of vitamin D and its analogues
on α-secretase shedding is not as congruent as found for amyloidogenic β-secretase cleavage. In our
study, calcifediol and paricalcitol were the only vitamin D species elevating non-amyloidogenic APP
processing, whereas the other vitamin D analogues showed no significant effect. Gezen-Ak et al. even
found an increase in mRNA and protein level of α-secretase ADAM10 in VDR siRNA-treated cortical
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neurons [42]. However, as additional metalloproteinases of the ADAM family have been identified as
α-secretases [9,12,79], further studies in vitamin D treated, vitamin D deficient or VDR deficient cells
are necessary to clarify the role of vitamin D and vitamin D analogues in α-secretase APP processing.
Beside Aβ anabolism impaired Aβ-degradation is discussed to contribute to sporadic AD. Vitamin D3,
as well as all analyzed vitamin D3 and vitamin D2 analogues, significantly elevated Aβ-degradation in
mouse neuroblastoma cells. Increased Aβ-degradation in presence of vitamin D3 or its analogues was
also obtained in vitamin D deficient mouse brains. Notably, we observed an increased gene expression
of NEP and elevated NEP activity in the presence of vitamin D and its analogues, indicating that the
Aβ-degrading enzyme NEP is affected by vitamin D and vitamin D3 and D2 analogues. These results
are in line with the finding of Briones et al. reporting an increase in the protein level of NEP in vitamin
D supplemented old rats [76]. Based on these findings, vitamin D and its analogues reduce total Aβ
level by pleiotropic mechanisms affecting Aβ anabolism and Aβ catabolism (Figure 6). Each of the
individual effects of the vitamin D analogues seem to be rather small and in some cases a significant
level is not reached. However, all of the observed mechanisms result in a reduction of total Aβ level,
which is highly significant and much more pronounced.
Int. J. Mol. Sci. 2017, 18, 2764 12 of 20 
 
in the presence of vitamin D and its analogues, indicating that the Aβ-degrading enzyme NEP is 
affected by vitamin D and vitamin D3 and D2 analogues. These results are in line with the finding of 
Briones et al. reporting an increase in the protein level of NEP in vitamin D supplemented old rats 
[76]. Based on these findings, vitamin D and its analogues reduce total Aβ level by pleiotropic 
mechanisms affecting Aβ anabolism and Aβ catabolism (Figure 6). Each of the individual effects of 
the vitamin D analogues seem to be rather small and in some cases a significant level is not reached. 
However, all of the observed mechanisms result in a reduction of total Aβ level, which is highly 
significant and much more pronounced. 
 
Figure 6. Model of the pleiotropic effects of vitamin D and analogues on Aβ-homeostasis. Vitamin D 
and analogues decrease amyloidogenic amyloid precursor protein (APP) processing by affecting β- 
and γ-secretase activity. The reduction of β-secretase activity is caused by a direct effect of vitamin D 
and its analogues on β-secretase activity combined with indirect effects on BACE1 gene expression 
and total BACE1 protein level. The γ-secretase activity is reduced by decreased gene expression of 
nicastrin responsible for the maturation of the heterotetrameric γ-secretase complex. A stimulation of 
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In summary, β-secretase cleavage is affected by a slight direct inhibitory effect on enzyme 
activity and a decrease in BACE1 expression and BACE1 protein level. γ-secretase activity is reduced 
by decreased gene expression of the γ-secretase component nicastrin. Furthermore, vitamin D and 
its analogues increase Aβ-degradation, substantiating the important role of vitamin D and its 
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Figure 6. Model of the pleiotropic effects of vitamin D and analogues on Aβ-homeostasis. Vitamin D
and analogues decrease amyloidogenic amyloid precursor protein (APP) processing by affecting β-
and γ-secretase activity. The reduction of β-secretase activity is caused by a direct effect of vitamin D
and its analogues on β-secretase activity combined with indirect effects on BACE1 gene expression
and total BACE1 protein level. The γ-secretase activity is reduced by decreased gene expression of
nicastrin responsible for the maturation of the heterotetrameric γ-secretase complex. A stimulation
of the non-amyloidogenic α-secretase processing of APP was found for 25(OH) vitamin D3 and the
vitamin D2 analogue paricalcitol. Total Aβ level in presence of vitamin D and analogues are further
reduced by increased Aβ-degradation.
In summary, β-secretase cleavage is affected by a slight direct inhibitory effect on enzyme activity
and a decrease in BACE1 expression and BACE1 protein level. γ-secretase activity is reduced by
decreased gene expression of the γ-secretase component nicastrin. Furthermore, vitamin D and its
analogues increase Aβ-degradation, substantiating the important role of vitamin D and its analogues
in Aβ homeostasis, and that supplementation with vitamin D3 or analogues of vitamin D3 and D2
might be protective against biological processes that are associated with AD. Notably, we found
a correlation between β-secretase activity, the rate-limiting step in Aβ-generation, Aβ-degradation,
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and total Aβ level in presence of vitamin D or its analogues, as determined by Pearson correlation
(r = 0.699, p = 0.081). In line, BACE1 protein level and Aβ-degradation correlates with the Aβ
level (r = 0.746, p = 0.054). However, the Pearson correlation did not reach significance. Regarding
vitamin D supplementation to prevent or treat AD, it is important to note that vitamin D3 also
interferes with inflammatory processes that are known to contribute to AD. A significant increase
in cytokine IL-1β level has been found in post mortem samples from AD patients with a maximum
response in those brain regions, frontal cortex, and hippocampus, where AD neuropathology is most
prominent [54]. Analyzing IL-1β, initiating inflammatory responses, we could show that vitamin D3
and vitamin D2 analogues, except paricalcitol, significantly reduced the pro-inflammatory IL-1β level.
This finding is consistent with the recent findings by Raha et al. reporting that vitamin D2 attenuates
Aβ25–35 induced pro-inflammatory cytokines, such as IL-1β, IL-6, and TNFα [27]. Furthermore,
a recent study, describing the increased level of pro-inflammatory IL-1β and decreased level of
anti-inflammatory IL-10 in old rats as compared to young animals, shows that this age-related change
in inflammatory states was mitigated by vitamin D supplementation [76]. This effect seems to be not
limited to pro-inflammatory cytokines, as it has recently been shown that 1,25-dihydroxyvitamin D3
upregulates IL-34 known to provide strong neuroprotective and survival signs in brain injury and
neurodegeneration [80].
In conclusion, our results substantiate vitamin D supplementation as an approach to prevent or
treat AD by reducing Aβ anabolism, elevating Aβ catabolism and the reduction of pro-inflammatory
cytokines. The analyzed vitamin D analogues reduce secreted Aβ level with a similar potency, but differ
partially in the effect strength of the underlying mechanisms, illustrating that individual AD patients
might profit in a different extend of vitamin D analogues. AD patients with reduced anti-amyloidogenic
β-secretase activity might benefit the most from supplementation with species like calcifediol and
paricalcitol, as these vitamin D species were the only vitamins increasing non-amyloidogenic APP
processing. According to our results, individuals with impaired Aβ-degradation might have the
highest benefits from vitamin D analogues, like calcipotriol and maxacalcitol, showing the strongest
effect on Aβ-degradation. In respect to β- and γ-secretase processing all of the vitamin D analogues
revealed similar results, indicating that individuals with increased amyloidogenic secretase activities
might benefit from the vitamin D analogues in a similar way.
However, it has to be emphasized that the differences in the effect strength are rather small, and
all of the analogues have been shown in respect to Aβ level to be similarly beneficial. Additionally,
the use of vitamin D analogues in respect to AD seems to have no therapeutical advantage when
compared to the use of calcifediol (or calcitriol), as no significant differences were found between
vitamin D analogues and vitamin D. Therefore, further medical indications or pharmacological aspects
of the vitamin D analogues should be taken into consideration as to which vitamin D analogue should
be applied. Related to this, factors like plasma half-life of individual analogues, the ability to pass
the blood-brain-barrier, the affinity for VDR as well as resorption, compatibleness, availability and
potential side-effects have to be considered [43,44]. Especially pharmacological factors and the ability
to pass the blood-brain-barrier might be even more relevant than the mechanistical differences of the
individual analogues, which has to be further evaluated in in vivo experiments and clinical studies.
4. Materials and Methods
4.1. Chemicals and Reagents
Calcifediol, and its analogues, alfacalcidol, calcipotriol, doxercalciferol, maxacalcitol, and
paricalcitol were purchased from MedChem Express (Monmouth Junction, NJ, USA), and all other
chemicals used in this study were acquired from Sigma-Aldrich (Taufkirchen, Germany), if not
stated otherwise.
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4.2. Cell Culture and Mice
For the cell based experiments human neuroblastoma SH-SY5Y wt cells, SH-SY5Y APP695
cells and N2a cells were cultivated in Dulbecco’s Modified Eagle’s Medium (DMEM), containing
10% fetal calf serum (FCS, PAN-Biotech, Aidenbach, Germany) and 0.1% non-essential amino acid
solution (MEM). For cultivating SH-SY5Y APP695, overexpressing the human APP695 isoform,
0.3 mg/mL hygromycin B (PAN-Biotech, Aidenbach, Germany) was added to the medium. The mouse
neuroblastoma cell line N2a was maintained in DMEM/10% FCS/0.1% MEM supplemented with
penicillin/streptomycin solution, 2 mM L-glutamine, and 1 mM sodium-pyruvat.
For the ex vivo experiments we used brains from female C57BL/6 wt mice (Charles River, Sulzfeld,
Germany) and vitamin D deficient mice. All animal experiments were approved by the “Landesamt
für Soziales, Gesundheit und Verbraucherschutz of the State of Saarland” (reference number 17/2011)
following the national guidelines for animal treatment. To create the vitamin D deficit, C57BL/6 mice
were fed as described, resulting in a 23% reduction in the 25(OH) vitamin D level [29]. After removing,
the brains were washed in 0.9% sodium chloride and directly frozen in liquid nitrogen. To establish the
homogenates, the mouse brains were slowly defrosted on ice, and afterwards were treated by Minilys
(Peqlab, Erlangen, Germany) in HPLC-grade H2O.
4.3. Vitamin D Incubations
4.3.1. Cell Culture
To minimize the influence of 25(OH) vitamin D3 from serum, FCS in DMEM was reduced to
0.1%–2.5% 16 h before incubation, dependent on subsequent experiments. Incubation with 100 nM
vitamin D or its analogues (dissolved in ethanol) was carried out for 24 h (8 + 16 h) in up to 2.5%
FCS/DMEM. Controls were treated with ethanol in a final concentration of 1‰, corresponding to the
concentration in the incubation media.
4.3.2. Mouse Brains or Purified Membranes
Equal amounts of mouse brain homogenates or postnuclear fractions, adjusted using bicinchoninic
acid assay, were incubated with 100 nM of vitamin D, its analogues or ethanol for 15 min at 4 ◦C.
4.4. Determination of Protein Concentration
The determination of the protein concentration of the samples was performed by using the
bicinchoninic acid assay (BCA), as described in [81].
4.5. Western Blot Experiments
Samples used for the WB experiments were adjusted to equal protein concentration in advance.
For the determination of BACE1, cell lysates were prepared by lysing cells in 150 mM NaCl,
50 mM Tris/HCl pH 7.4, 2 mM EDTA, 0.1% NP-40, 0.1% Triton-X 100. For the determination of total
secreted Aβ level and sAPPβ conditioned media were used.
The following antibodies were used for WB analysis: W02 antibody (5 µg/mL; Millipore, Billerica,
MA, USA), anti-sAPPβ: Mbs492139 (1:250; MyBioSource, San Diego, CA, USA), BACE1: ab2077
(1:1000; abcam, Cambridge, UK), anti-actin ab1801 (1:1000; abcam), anti-rabbit IgG HRP Conjugate
W401B (1:5000; Promega, Mannheim, Germany) and anti-mouse P0260 (Dako, Hamburg, Germany).
Aβ levels were detected by performing immunoprecipitation of conditioned media before WB
analysis. Therefore, 20 µL protein G-Sepharose and W02 antibody (5 µg/mL) were used.
Enhanced chemiluminescense (ECL)-method (Perkin Elmer, Rodgau-Jügesheim, Germany) was
used to detect proteins. Densitometrically quantification was performed by using Image Gauge V3.45
software (Fujifilm, Düsseldorf, Germany).
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4.6. Determination of Total Aβ-Degradation
For measuring the total degradation of Aβ, human synthetic Aβ40 (Bachem, Bubendorf,
Switzerland) was added to murine samples. After a determined period of time, non-degraded
human Aβ was detected by WB analysis using W02 antibody, which binds specifically to human Aβ,
as described before [82]. Human Aβ differs in the W02 epitope compared to murine Aβ. Therefore,
no endogenous produced Aβ is detected by the use of murine N2a cells.
4.6.1. Determination of Total Aβ-Degradation in N2a wt Cells.
After cultivation of mouse neuroblastoma N2a wt cells in reduced FCS (0.1%) /DMEM for 6 h,
cells were incubated with 100 nM vitamin D, its analogues or ethanol for 18 h and additionally 6 h in
the presence of 0.5 µg/mL human synthetic Aβ40.
4.6.2. Determination of Total Aβ-Degradation in Deficient Mouse Brains
Deficient mouse brain homogenates were incubated as described earlier and treated for 1 h with
synthetic Aβ40 in a final concentration of 1 µg/mL, 1 µM β-inhibitor, and 20 µM γ-inhibitor (Merck
Millipore, Billerica, MA, USA).
4.7. Secretase Activity Assays
4.7.1. Determination of α-, β- and γ-Secretase Activity in Living SH-SY5Y Cells
Secretase activity assays were performed, as described before [82,83]. Following the incubation,
cells were washed twice with prewarmed imaging solution containing 140 mM NaCl, 5 mM KCl,
8 mM CaCl2, 1 mM MgCl2, 20 mM HEPES, pH 7.4. Afterwards, 100 µL (α)/50 µL (β and γ) imaging
solution mixed with 3 µM α-secretase substrate (Calbiochem, No. 565767), 20 µM β-secretase substrate
(Calbiochem, No. 565758) or 6,25 µM γ-secretase substrate (Calbiochem, No. 565764) was added.
The resulting fluorescence was determined continuously at excitation wavelengths of 340 ± 10 nm (α),
345 ± 5 nm (β), 355 ± 10 nm (γ) and emission wavelengths of 490 ± 10 nm (α), 500 ± 5 nm (β),
440± 10 nm (γ) under light preclusion and at 37 ◦C in a Safire2 Fluorometer (Tecan, Crailsheim, Germany).
4.7.2. Determination of β-Secretase Activity in Isolated SH-SY5Y Membranes
Measurements have been done as published in [23]. After homogenization of SH-SY5Y cells in
sucrose buffer with Minilys (Peqlab, Erlangen, Germany) using ceramic beads, homogenates were
adjusted to an equal protein amount by bicinchoninic acid assay and postnuclear fractions (PNFs) were
isolated by sucrose density centrifugation. PNFs were incubated with calcifediol or its analogues for
15 min at 4 ◦C, and for pelleting membranes ultracentrifuged at 55,000 rpm for 75 min at 4 ◦C. Following,
membranes were resuspended using glass beads in Minilys. For determination of β-secretase activity
20 µM specific β-secretase substrate (described above) was added to 125 µg of protein diluted 1:1 with
1 × PBS pH 4.5. Fluorescence was measured as described before.
4.8. RT-PCR Experiments
Quantitative real-time (RT) PCR has been done, as published in [19]. After isolation of total
RNA from incubated SH-SY5Y cells using TRIzol Reagent (Thermo Fisher Scientific; Waltham, MA,
USA), 2 µg RNA were reversed transcribed using the High-Capacity cDNA Reverse Transcription Kit
(Thermo Fisher Scientific). RT-PCR using the Fast SYBR Green Master Mix (Applied Biosystems, Foster
City, CA, USA) was performed on a PikoReal Real-Time PCR System (Thermo Fisher Scientific) and the
following primers were used. β-actin: forward 5′-CTT CCT GGG CAT GGA GTC-3′, reverse 5′-AGC
ACT GTG TTG GCG TAC AG-3′; TATA-box binding protein (TBP): forward 5′-CGG AGA GTT CTG
GGA TTG T-3′, reverse 5′-GGT TCG TGG CTC TCT TAT C-3′; β-site APP-cleaving enzyme 1 (BACE1):
forward 5′-GCC TAT GCT GAG ATT GCC AGG-3′, reverse 5′-GGA GAA GAG GTT GGG AAC
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GTG-3′; nicastrin: forward 5′-CTG TAC GGA ACC AGG TGG AG-3′, reverse 5′-GAG AGG CTG GGA
CTG ATT TG-3′; neprilysin (NEP): forward 5′-GAT CAG CCT CTC GGT CCT TG-3′, reverse 5′-TGT
TTT GGA TCA GTC GAG CAG-3′ (Eurofins MWG Operon, Eberberg, Germany). Two house-keeping
genes (β-actin and TBP) were used to exclude RT efficiency differences. The obtained results were
normalized to the β-actin/TBP ratio and the 2−(∆∆Ct) method was used to calculate expression changes.
4.9. Neprilysin Activity Assay
Measurement of NEP activity was performed as published in Miners et al. [84], with minor
modifications utilizing the anti-NEP antibody AF1182 (R&D Systems, Minneapolis, MN, USA) and
5 µM MCA-RPPGFSAFK(DNP)-OH fluorogenic peptide substrate (R&D Systems, Minneapolis, MN,
USA). Cells were chemical lysed in lysis buffer containing 0.5% TritonX-100, 20 nM Tris pH 7.4, 10%
sucrose and fluorescence at an excitation wavelength of 320 ± 10 nm, and an emission wavelength of
405 ± 10 nm was measured in a Safire2 Fluorometer (Tecan, Crailsheim, Germany).
4.10. Enzyme-Linked Immunosorbent Assay (ELISA)
The level of cytokine IL-1β was measured in the medium of incubated SH-SY5Y wt cells using
the Human IL-1 beta ELISA Kit (Abcam, Cambridge, UK).
4.11. Lactate Dehydrogenase (LDH) Activity Assay
The Cytotoxicity Detection Kit (LDH) from Roche (Basel, Schweiz), a colorimetric assay for the
measurement of lactate dehydrogenase (LDH) release from cells, was used according manufacturer’s
instructions to quantify cell death and lysis after incubation with different vitamin D concentrations.
4.12. Data Analysis
All quantified data represent an average of at least three independent experiments. Error bars
represent standard error of the mean. Statistical significance was calculated using two-tailed Student’s
t test, ANOVA, and post hoc Tests for multiple comparison analysis. The normality of the data distribution
was tested with Shapiro Wilk test. Significance was set at * p≤ 0.05; ** p≤ 0.01 and *** p≤ 0.001.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/12/2764/s1.
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